MiMedx Group (MDXG) Delivers Record Full Year Revenue

​MiMedx Group, Inc. (NASDAQ:MDXG) is one of the  Best 52-Week Low Penny Stocks to Invest In. On February 25, MiMedx Group, Inc. (NASDAQ:MDXG) delivered record quarterly and full-year revenue and profitability. This was driven by the company’s wound care and surgical segments, both delivering double-digit growth.

​The company grew its Q4 revenue by 27.11% year-over-year to reach $118.1 million and topped the Street’s target by $11.32 million. The EPS of $0.10 also exceeded expectations by $0.01. The growth was driven by 28% year-over-year increase in wound care and 25% increase in surgical segment revenue. Notably, the gross profit margins improved 200 basis points to reach 86% for Q4, driven by better product mix compared to a year ago.

​For fiscal 2026, the company expects revenue in the range of $340 million to $360 million, while the adjusted EBITDA margin is expected in the range of mid to high teens.

​MiMedx Group, Inc. (NASDAQ:MDXG) is a U.S. biomedical company that develops and distributes advanced placental tissue allografts for wound care, surgical, and burn applications. Its products, using proprietary processing methods, help clinicians treat chronic and hard-to-heal wounds.

While we acknowledge the potential of MDXG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. Follow Insider Monkey on Google News.